Table 1. Clinical, immunophenotypic and genetic features of EBV+ DLBCL and EBV− DLBCL.
| All patients | ≤50 years | >50 years | |||||||
|---|---|---|---|---|---|---|---|---|---|
| n=46 | n=533 | P value | n=16 | n=104 | P value | n=30 | n=429 | P value | |
| EBV+ DLBCL | EBV− DLBCL | EBV+ DLBCL | EBV− DLBCL | EBV+ DLBCL | EBV− DLBCL | ||||
| Median age, years (range) | 61 (21 - 86) | 63 (16 - 92) | 0.1481 | 43 (21-50) | 42 (16-50) | 0.8161 | 66 (53-86) | 51 (67 - 92) | 0.6916 |
| Men:women | 25:21 | 306:227 | 0.7567 | 7:9 | 69:35 | 0.1581 | 18:12 | 237:192 | 0.7054 |
| B symptoms | 16 (38%) | 154 (33%) | 0.4981 | 7 (47%) | 29 (31%) | 0.2248 | 9 (33%) | 125 (33%) | 1 |
| LDH elevation | 31 (70%) | 304 (63%) | 0.4133 | 12 (75%) | 65 (69%) | 0.5458 | 19 (68%) | 239 (62%) | 0.5525 |
| Stage III/IV | 28 (62%) | 266 (52%) | 0.2133 | 9 (56%) | 50 (51%) | 0.5869 | 19 (66%) | 216 (52%) | 0.1807 |
| ECOG ≥2 | 11 (27%) | 72 (16%) | 0.0783 | 2 (13%) | 11 (13%) | 1 | 9 (36%) | 61 (16%) | 0.0251 |
| IPI >2 | 16 (38%) | 221 (42%) | 0.6295 | 2 (13%) | 33 (33%) | 0.2204 | 14 (52%) | 188 (45%) | 0.5506 |
| ≥2 EN involvement | 9 (20%) | 114 (22%) | 0.8522 | 3 (19%) | 30 (30%) | 0.5491 | 6 (21%) | 84 (20%) | 0.8139 |
| Size ≥ 6cm | 12 (36%) | 130 (33%) | 0.7006 | 5 (38%) | 25 (33%) | 0.7447 | 7 (35%) | 105 (32%) | 0.8086 |
| CR/PR | 39 (89%) | 471 (88%) | 1 | 12 (86%) | 93 (89%) | 0.637 | 27 (90%) | 378 (88%) | 1 |
| GCB phenotype | 14 (42%) | 280 (54%) | 0.2806 | 5 (45%) | 69 (68%) | 0.1793 | 9 (41%) | 211 (50%) | 0.5131 |
| ABC phenotype | 19 (58%) | 243 (46%) | 6 (55%) | 32 (32%) | 13 (59%) | 211 (50%) | |||
| CD30 expression | 16 (44%) | 66 (14%) | <0.001 | 6 (43%) | 16 (18%) | 0.0727 | 10 (45%) | 50 (14%) | 0.0005 |
| p50 expression | 14 (61%) | 150 (34%) | 0.0124 | 3 (43%) | 32 (37%) | 1 | 11 (69%) | 118 (33%) | 0.0056 |
| p65 expression | 3 (11%) | 92 (20%) | 0.3252 | 0 (0%) | 24 (28%) | 0.1849 | 3 (15%) | 68 (18%) | 1 |
| c-Rel expression | 5 (23%) | 103 (23%) | 1 | 1 (14%) | 16 (19%) | 1 | 4 (27%) | 87 (24%) | 0.7673 |
| pSTAT3 expression | 9 (39%) | 65 (16%) | 0.0079 | 3 (43%) | 11 (14%) | 0.0818 | 6 (38%) | 54 (16%) | 0.0389 |
| BCL2 expression | 12 (41%) | 225 (49%) | 0.4485 | 3 (38%) | 33 (37%) | 1 | 9 (43%) | 192 (52%) | 0.5024 |
| BCL6 expression | 14 (50%) | 417 (82%) | 0.0002 | 3 (38%) | 76 (80%) | 0.016 | 11 (52%) | 241 (82%) | 0.0024 |
| p53 expression | 10 (43%) | 163 (36%) | 0.5112 | 2 (29%) | 31 (36%) | 1 | 8 (39%) | 132 (36%) | 0.8072 |
| MYC expression | 17 (61%) | 293 (64%) | 0.6913 | 3 (43%) | 47 (54%) | 0.702 | 14 (67%) | 246 (66%) | 1 |
| MYC/BCL2 expression | 8 (29%) | 152 (34%) | 0.6823 | 1 (14%) | 21 (24%) | 1 | 7 (33%) | 131 (36%) | 1 |
| BCL2 rearrangement | 1 (5%) | 77 (19%) | 0.1456 | 0 (0%) | 11 (14%) | 1 | 1 (6%) | 66 (20%) | 0.3257 |
| BCL6 rearrangement | 1 (6%) | 119 (34%) | 0.026 | 0 (0%) | 18 (25%) | 0.5676 | 1 (8%) | 101 (36%) | 0.0628 |
| MYC rearrangement | 2 (11%) | 38 (9%) | 0.6727 | 0 (0%) | 8 (10%) | 1 | 2 (14%) | 30 (8%) | 0.3571 |
| *Double hit | 0 (0%) | 16 (4%) | 1 | 0 (0%) | 3 (4%) | 1 | 0 (0%) | 13 (4%) | 1 |
| TP53 mutation | 2 (10%) | 107 (23%) | 0.2715 | 0 (0%) | 18 (20%) | 1 | 2 (17%) | 89 (23%) | 0.3805 |
LDH; lactate dehydrogenase, ECOG; Eastern Cooperative Oncology Group, IPI; International Prognostic Index, EN; Extranodal, CR; complete remission, PR; partial remission, GCB; germinal center B-cell-like phenotype, ABC; activated B-cell-like phenotype, pSTAT3; phosphorylated signal transducer and activator of transcription 3.
*
Double hit; MYC rearrangement with either BCL2 or BCL6 rearrangement